Supreme Court Ruling Pushes Myriad (MYGN), Genomic (GHDX), Labcorp (LH) Shares Lower
Tweet Send to a FriendGet Alerts MYGN Hot Sheet
Trade MYGN Now!
Traders should be watching a select group of stocks in the Biotech and Drug sector following a Supreme Court ruling in favor of Mayo Clinic related to two patents from Nestle's Prometheus unit which were found invalid as they cover natural phenomena. The ruling will likely impact patent protection within the personalized medicine products group.
Shares of Myriad Genetics (Nasdaq: MYGN), Genomic Health (Nasdaq: GHDX) and Labcorp (NYSE: LH) have all dipped following the headlines.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares of Myriad Genetics (Nasdaq: MYGN), Genomic Health (Nasdaq: GHDX) and Labcorp (NYSE: LH) have all dipped following the headlines.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Intuitive Surgical (ISRG) Jury Reaches Positive Verdict in Robot Case; Shares Rise
- Major ResCap Creditor MBIA (MBI) Trades Higher on Ally Settlement
- Canadian Solar (CSIQ) Continues Higher Following Arbitration Win Over LDK (LDK)
Create E-mail Alert Related Categories
Corporate News, Litigation, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
